1-(甲氧基甲基)哌啶 | 18811-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(甲氧基甲基)哌啶
• 英文名称: 1-(methoxymethyl)piperidine
• 英文别名: N-(Methoxymethyl)-piperidin
• CAS: 18811-61-5
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: VEPGOXSEFOHRBS-UHFFFAOYSA-N

物化性质

• 沸点：
  155-157 °C(Press: 740 Torr)
• 密度：
  0.913±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(甲氧基甲基)哌啶 在 甲醇 、 氘代3-氨基-5-吗啉-4-甲基-恶唑-2-啉酮 作用下， 生成 tris(N-piperidinomethyl)phosphine
  参考文献：
  名称：

  三(三甲基甲硅烷基)膦的1-杂烷基化

  摘要：

  使用杂取代的甲胺、氯甲基烷基醚、氯甲酸甲酯、多聚甲醛和二烷基甲酰胺对三（三甲基甲硅烷基）膦的 1-杂烷基化进行了彻底研究。合成三（二烷基氨基甲基）膦、三（烷氧基甲基）膦、三（甲氧基羰基）膦和几种膦亚乙基的便捷方法基于三（三甲基甲硅烷基）膦作为一种有价值的合成子的 1-杂烷基化被提出。© 2010 Wiley Periodicals, Inc. 杂原子化学 21:441–445, 2010; 在 wileyonlinelibrary.com 上在线查看这篇文章。DOI 10.1002/hc.20636

  DOI：

  10.1002/hc.20636
• 作为产物：
  描述：

  哌啶 、 alkaline earth salt of/the/ methylsulfuric acid 以 甲醇 为溶剂， 以65.5%的产率得到1-(甲氧基甲基)哌啶
  参考文献：
  名称：

  Cyanomethylamines and azidomethylamines: new general methods of the synthesis and transformations

  摘要：

  Simple and efficient methods have been developed to obtain cyanomethylamines and azidomethylamines using reactions of methoxymethylamines with TMSCN and TMSN3, respectively. In the case of dimethylformamide dimethylacetal, only one MeO group was substituted with CN, and an unexpected direction of the subsequent azidation was found. Adducts of azidomethylamines with DMAD were studied, and the base-catalyzed isomerization of symmetric triazoles into non-symmetric ones was revealed.

  DOI：

  10.1016/j.mencom.2009.09.018

文献信息

• Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20190077784A1

  公开（公告）日：2019-03-14

  The invention discloses compounds of Formula (I), wherein A 1 , R 1 , R 2 , R 3 , R 4 , and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明揭示了式（I）的化合物， 其中A 1 ，R 1 ，R 2 ，R 3 ，R 4 和n如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• Enantioselective Synthesis of α‐Aryl‐β ² ‐Amino‐Esters by Cooperative Isothiourea and Brønsted Acid Catalysis
  作者：Feng Zhao、Chang Shu、Claire M. Young、Cameron Carpenter‐Warren、Alexandra M. Z. Slawin、Andrew D. Smith

  DOI：10.1002/anie.202016220

  日期：2021.5.17

  The synthesis of α‐aryl‐β2‐amino esters through enantioselective aminomethylation of an arylacetic acid ester in high yields and enantioselectivity via cooperative isothiourea and Brønsted acid catalysis is demonstrated. The scope and limitations of this process are explored (25 examples, up to 94 % yield and 96:4 er), with applications to the synthesis of (S)‐Venlafaxine⋅HCl and (S)‐Nakinadine B.

  证明了通过异硫脲和布朗斯台德酸协同催化，对芳基乙酸酯进行对映选择性氨甲基化，以高收率和对映选择性合成α-芳基-β 2 -氨基酯。探索了该过程的范围和局限性（25 个示例，产率高达 94% 和 96:4 er），并应用于 ( S )-文拉法辛·HCl 和 ( S )-Nakinadine B的合成。机理研究是一致的遵循 C(1)-烯醇化铵途径，而不是替代的动态动力学解析过程。对照研究表明 (i) 观察到催化剂和产物 er 之间存在线性效应；(ii)酰基铵离子可以用作预催化剂；（iii）可逆的异硫脲加成到原位生成的亚胺离子上，产生可用作生产性预催化剂的非循环中间体。
• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2014114185A1

  公开（公告）日：2014-07-31

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

  本发明提供了根据式I或其药学上可接受的盐制备的Bruton's酪氨酸激酶（Btk）抑制剂化合物，或包含这些化合物的药物组合物，并且提供了这些化合物在治疗中的应用。具体而言，本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。